


Amendments to the claims:

1. (Previously presented) A method for treating a subject with an allergic condition, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) below:



wherein:

$R^1$  is hydrogen, azido, halogen,  $C_{1-5}$  alkoxy, hydroxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^7R^8N$ ,  $C_{2-8}$  acyl,  $R^9OC=O$ ,  $R^{10}R^{11}NC=O$ , or  $R^{10}R^{11}NSO_2$ ; or  $R^1$  is taken together with W as described below;

$R^2$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  haloalkyl, cyano, or  $R^{48}R^{49}N$ ;

alternatively,  $R^1$  and  $R^2$  can be taken together to form an optionally substituted 5- to 7- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;

each of  $R^3$  and  $R^4$  is independently hydrogen or  $C_{1-5}$  alkyl;

each of  $R^5$  and  $R^6$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkylthio, halogen, or a 4-7 membered carbocyclyl or heterocyclyl;

alternatively,  $R^5$  and  $R^6$  can be taken together to form an optionally substituted 6-membered carbocyclic ring, which ring may be unsaturated or aromatic, and may be optionally substituted with between one and three substituents independently selected from halo, cyano, amino, nitro,  $R^{40}$ ,  $R^{40}O-$ ,  $R^{40}S-$ ,  $R^{40}O(C_{1-5} \text{ alkylene})-$ ,  $R^{40}O(C=O)-$ ,  $R^{40}(C=O)-$ ,  $R^{40}(C=S)-$ ,

$R^{40}(C=O)O-$ ,  $R^{40}O(C=O)(C=O)-$ ,  $R^{40}SO_2$ ,  $NHR^{62}(C=NH)-$ ,  $NHR^{62}SO_2-$ , and  $NHR^{62}(C=O)-$ ;

$R^{40}$  is H, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, phenyl, benzyl, phenethyl, C<sub>1-5</sub> heterocyclyl, (C<sub>1-5</sub> heterocyclyl)C<sub>1-5</sub> alkylene, amino, or mono- or di(C<sub>1-5</sub> alkyl)amino, or  $R^{58}OR^{59}-$ , wherein  $R^{58}$  is H, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, phenyl, benzyl, phenethyl, C<sub>1-5</sub> heterocyclyl, or (C<sub>1-5</sub> heterocyclyl)C<sub>1-6</sub> alkylene and  $R^{59}$  is C<sub>1-5</sub> alkylene, phenylene, or divalent C<sub>1-5</sub> heterocyclyl; and

$R^{62}$  can be H in addition to the values for  $R^{40}$ ;

$R^7$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, naphthyl, C<sub>1-5</sub> heterocyclyl, C<sub>2-8</sub> acyl, aroyl,  $R^{27}OC=O$ ,  $R^{28}R^{29}NC=O$ ,  $R^{27}SO$ ,  $R^{27}SO_2$ , or  $R^{28}R^{29}NSO_2$ ;

$R^8$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, or C<sub>1-5</sub> heterocyclyl; alternatively,  $R^7$  and  $R^8$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

$R^9$  is C<sub>1-5</sub> alkyl, phenyl, naphthyl, or C<sub>1-5</sub> heterocyclyl;

$R^{21}$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, naphthyl, C<sub>1-5</sub> heterocyclyl, C<sub>2-8</sub> acyl, aroyl,  $R^{30}OC=O$ ,  $R^{31}R^{32}NC=O$ ,  $R^{30}SO$ ,  $R^{30}SO_2$ , or  $R^{31}R^{32}NSO_2$ ;

$R^{22}$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, or C<sub>1-5</sub> heterocyclyl; alternatively,  $R^{21}$  and  $R^{22}$  can be taken together to form an optionally substituted 4- to 7-membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

each of  $R^{23}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{30}$ ,  $R^{33}$ ,  $R^{44}$ ,  $R^{45}$ , and  $R^{50}$  is C<sub>1-5</sub> alkyl, phenyl, naphthyl, or C<sub>1-5</sub> heterocyclyl;


$R^{24}$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, naphthyl, C<sub>1-5</sub> heterocyclyl, C<sub>2-8</sub> acyl, aroyl,  $R^{33}OC=O$ ,  $R^{34}R^{35}NC=O$ ,  $R^{33}SO$ ,  $R^{33}SO_2$ , or  $R^{34}R^{35}NSO_2$ ;

$R^{25}$  is hydrogen, C<sub>1-5</sub> alkyl, C<sub>3-5</sub> alkenyl, phenyl, or C<sub>1-5</sub> heterocyclyl; alternatively,  $R^{24}$  and  $R^{25}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;


each of  $R^{10}$  and  $R^{11}$  is independently hydrogen, C<sub>1-5</sub> alkyl, C<sub>2-5</sub> alkenyl, phenyl, or C<sub>1-5</sub> heterocyclyl;

- alternatively,  $R^{10}$  and  $R^{11}$  or can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of  $R^{28}$ ,  $R^{29}$ ,  $R^{31}$ ,  $R^{32}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{46}$ ,  $R^{47}$ ,  $R^{51}$  and  $R^{52}$  is independently hydrogen,  $C_{1-5}$  alkyl, phenyl, or  $C_{1-5}$  heterocyclyl;
- alternatively,  $R^{28}$  and  $R^{29}$ ,  $R^{31}$  and  $R^{32}$ ,  $R^{34}$  and  $R^{35}$ ,  $R^{46}$  and  $R^{47}$ , or  $R^{51}$  and  $R^{52}$ , independently, can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- n is 1;
- G represents  $C_{3-6}$  alkenediyl or  $C_{3-6}$  alkanediyl, optionally substituted with hydroxy, halogen,  $C_{1-5}$  alkyl,  $C_{1-5}$  alkoxy, oxo, hydroximino,  $CO_2R^{60}$ ,  $R^{60}R^{61}NCO_2$ , (L)- $C_{1-4}$  alkylene-, (L)- $C_{1-5}$  alkoxy,  $N_3$ , or [(L)- $C_{1-5}$  alkylene]amino;
- each of  $R^{60}$  and  $R^{61}$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, benzyl, phenethyl, or  $C_{1-5}$  heterocyclyl; alternatively  $R^{60}$  and  $R^{61}$ , can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- L is amino, mono- or di- $C_{1-5}$  alkylamino, pyrrolidinyl, morpholinyl, piperidinyl, homopiperidinyl, or piperazinyl, where available ring nitrogens may be optionally substituted with  $C_{1-5}$  alkyl, benzyl,  $C_{2-5}$  acyl,  $C_{1-5}$  alkylsulfonyl or  $C_{1-5}$  alkyloxycarbonyl;
- X is nitrogen or  $R^{12}C$ ;
- Y is nitrogen or  $R^{13}C$ ;
- Z is nitrogen or  $R^{14}C$ ;
- $R^{12}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{21}R^{22}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$  alkylene,  $R^{23}OC=O$ ,  $R^{23}O(C=O)NH-$ ,  $R^{23}SO$ ,  $R^{22}NHCO-$ ,  $R^{22}NH(C=O)NH-$ ,  $R^{23}(C_{1-4}$  alkylene) $NHCO-$ ,  $R^{23}SO_2$ , or  $R^{23}SO_2NH-$ ;
- $R^{13}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{42}R^{43}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl, ( $C_{1-5}$  heterocyclyl) $C_{1-5}$

- alkylene,  $R^{44}OC=O$ ,  $R^{44}O(C=O)NH-$ ,  $R^{44}SO$ ,  $R^{43}NHCO-$ ,  $R^{43}NH(C=O)NH-$ ,  $R^{44}(C_{1-4} \text{ alkylene})NHCO-$ ,  $R^{44}SO_2$ , or  $R^{44}SO_2NH-$ ;
- $R^{14}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, nitro,  $R^{24}R^{25}N$ ,  $C_{2-8}$  acyl,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  heterocyclyl,  $(C_{1-5} \text{ heterocyclyl})C_{1-5}$  alkylene,  $R^{26}OC=O$ ,  $R^{26}O(C=O)NH-$ ,  $R^{26}SO$ ,  $R^{25}NHCO-$ ,  $R^{25}NH(C=O)NH-$ ,  $R^{26}(C_{1-4} \text{ alkylene})NHCO-$ ,  $R^{26}SO_2$ , or  $R^{26}SO_2NH-$ ;  
alternatively,  $R^{12}$  and  $R^{13}$  or  $R^{12}$  and  $R^2$  or  $R^{13}$  and  $R^{14}$  can be taken together to form an optionally substituted 5- to 6- membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic;
- Ar represents a monocyclic or bicyclic aryl or heteroaryl ring, optionally substituted with between 1 and 3 substituents selected from halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, cyano, azido, nitro,  $R^{15}R^{16}N$ ,  $R^{17}SO_2$ ,  $R^{17}S$ ,  $R^{17}SO$ ,  $R^{17}OC=O$ ,  $R^{15}R^{16}NC=O$ ,  $C_{1-5}$  haloalkyl,  $C_{1-5}$  haloalkoxy,  $C_{1-5}$  haloalkylthio, and  $C_{1-5}$  alkylthio;
- $R^{15}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, benzyl,  $C_{1-5}$  heterocyclyl,  $C_{2-8}$  acyl, aroyl,  $R^{53}OC=O$ ,  $R^{54}R^{55}NC=O$ ,  $R^{53}S$ ,  $R^{53}SO$ ,  $R^{53}SO_2$ , or  $R^{54}R^{55}NSO_2$ ;
- $R^{16}$  is hydrogen,  $C_{1-5}$  alkyl,  $C_{3-5}$  alkenyl, phenyl, benzyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{15}$  and  $R^{16}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- each of  $R^{17}$  and  $R^{53}$  is  $C_{1-5}$  alkyl, phenyl, or  $C_{1-5}$  heterocyclyl;
- each of  $R^{54}$  and  $R^{55}$  is independently hydrogen,  $C_{1-5}$  alkyl,  $C_{2-5}$  alkenyl, phenyl, benzyl, or  $C_{1-5}$  heterocyclyl;  
alternatively,  $R^{54}$  and  $R^{55}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;
- W represents  $SO_2$ ,  $C=O$ ,  $CHR^{20}$ , or a covalent bond; or W and  $R^1$ , taken together with the 6-membered ring to which they are both attached, form one of the following two formulae:



(I)(a)



(I)(b)

wherein  $X_a$  is O, S, or N; and  $X_b$  is O, S or  $\text{SO}_2$ ;

$R^{20}$  is hydrogen,  $\text{C}_{1-5}$  alkyl, phenyl, benzyl, naphthyl, or  $\text{C}_{1-5}$  heterocyclyl;

$R^{42}$  is hydrogen,  $\text{C}_{1-5}$  alkyl,  $\text{C}_{3-5}$  alkenyl, phenyl, naphthyl,  $\text{C}_{1-5}$  heterocyclyl,  $\text{C}_{2-8}$  acyl, aroyl,  $R^{45}\text{OC}=\text{O}$ ,  $R^{46}R^{47}\text{NC}=\text{O}$ ,  $R^{45}\text{SO}$ ,  $R^{45}\text{SO}_2$ , or  $R^{46}R^{47}\text{NSO}_2$ ;

$R^{43}$  is hydrogen,  $\text{C}_{1-5}$  alkyl,  $\text{C}_{3-5}$  alkenyl, phenyl, or  $\text{C}_{1-5}$  heterocyclyl;

alternatively,  $R^{42}$  and  $R^{43}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic;

$R^{44}$  is  $\text{C}_{1-5}$  alkyl,  $\text{C}_{2-5}$  alkenyl, phenyl, naphthyl, or  $\text{C}_{1-5}$  heterocyclyl;

$R^{48}$  is hydrogen,  $\text{C}_{1-5}$  alkyl,  $\text{C}_{3-5}$  alkenyl, phenyl, naphthyl,  $\text{C}_{1-5}$  heterocyclyl,  $\text{C}_{2-8}$  acyl, aroyl,  $R^{50}\text{OC}=\text{O}$ ,  $R^{51}R^{52}\text{NC}=\text{O}$ ,  $R^{50}\text{SO}$ ,  $R^{50}\text{SO}_2$ , or  $R^{51}R^{52}\text{NSO}_2$ ;

$R^{49}$  is hydrogen,  $\text{C}_{1-5}$  alkyl,  $\text{C}_{3-5}$  alkenyl, phenyl, or  $\text{C}_{1-5}$  heterocyclyl;

alternatively,  $R^{48}$  and  $R^{49}$  can be taken together to form an optionally substituted 4- to 7- membered heterocyclic ring, which ring may be saturated, unsaturated or aromatic; and

wherein each of the above hydrocarbyl or heterocarbyl groups, unless otherwise indicated, and in addition to any specified substituents, is optionally and independently substituted with between 1 and 3 substituents selected from methyl, halomethyl, hydroxymethyl, halo, hydroxy, amino, nitro, cyano,  $\text{C}_{1-5}$  alkyl,  $\text{C}_{1-5}$  alkoxy,  $-\text{COOH}$ ,  $\text{C}_{2-6}$  acyl,  $[\text{di}(\text{C}_{1-4} \text{ alkyl})\text{amino}]\text{C}_{2-5} \text{ alkylene}$ ,  $[\text{di}(\text{C}_{1-4} \text{ alkyl})\text{amino}] \text{C}_{2-5} \text{ alkyl-NH-CO-}$ , and  $\text{C}_{1-5}$  haloalkoxy;

or a pharmaceutically acceptable salt, ester, or amide thereof.

2. (Previously presented) A method of claim 1, wherein each of  $R^3$  and  $R^4$  is hydrogen; Ar represents a six membered ring, optionally substituted with between 1 and 2 substituents selected from halogen,  $C_{1-5}$  alkyl, cyano, nitro,  $R^{15}R^{16}N$ ,  $CF_3$  and  $OCF_3$ ;  $R^{12}$  is hydrogen,  $R^{23}SO$ , or  $R^{23}SO_2$ ;  $R^{13}$  is hydrogen,  $R^{44}SO$ , or  $R^{44}SO_2$ ;  $R^{14}$  is hydrogen, halogen,  $C_{1-5}$  alkoxy,  $C_{1-5}$  alkyl, cyano, nitro, or  $R^{24}R^{25}N$ ; and G is  $C_3$  alkanediyl, optionally substituted with hydroxy, (L)- $C_{1-5}$  alkyloxy-, or (L)- $C_{1-5}$  alkylamino.

3. (Previously presented) A method of claim 2, wherein Ar is phenyl.

4. (Canceled)

5. (Canceled)

6. (Currently amended) A method of claim 1, wherein said compound is selected from :

1-[3-(3,4-Dichloro-phenyl)-pyrazol-1-yl]-3-(4-o-tolyl-piperazin-1-yl)-propan-2-ol.

---

7. (Canceled)

8. (Previously presented) A method of claim 1, wherein said pharmaceutical composition is formulated in a dosage amount appropriate for the treatment of an allergic condition.
9. (Original) A method of claim 1, wherein said condition is asthma.
10. (Original) A method of claim 2, wherein said condition is asthma.
11. (Original) A method of claim 3, wherein said condition is asthma.
12. (Original) A method of claim 7, wherein said condition is asthma.